Laura K. Aguilar - 29 Jul 2021 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Medical Officer
Signature
/s/ John Canepa, Attorney-in-Fact
Issuer symbol
CADL
Transactions as of
29 Jul 2021
Net transactions value
$0
Form type
4
Filing time
02 Aug 2021, 20:04:05 UTC
Previous filing
26 Jul 2021
Next filing
10 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Conversion of derivative security +56,096 +6.4% 931,039 29 Jul 2021 Direct F1, F2
holding CADL Common Stock 2,013,100 29 Jul 2021 By Laura K. Aguilar 2020 Irrevocable Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Series B Preferred Stock Conversion of derivative security $0 -137,881 -100% $0.000000* 0 29 Jul 2021 Common Stock 56,096 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
F2 Includes 32,399 shares of common stock held jointly with spouse.
F3 Shares held by the Laura K. Aguilar 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney